CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Image-guided minimally invasive lumbar decompression (IG-MLD / MILD)

This policy governs coverage stance for percutaneous image-guided minimally invasive lumbar decompression (IG-MLD, aka MILD/PILD) for treatment of central lumbar spinal stenosis and specifies differences for Commercial products versus BlueCHiP for Medicare members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyImage-guided minimally invasive lumbar decompression (IG-MLD / MILD)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 10, 2015

Next Review DateN/A

Key ActionBill Medicare clinical study services with modifier Q0 (or Q1 as appropriate) and follow CMS clinical trial documentation when treating BlueCHiP for Medicare members in an approved study.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not medically necessarycommercial stance

Covered in CMS trialMedicare CED

Study codes listedMedicare coding

Central stenosis onlyClinical limit

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Commercial — Not Medically Necessary

Covered when ALL of the following are met

Commercial - Not Medically Necessary: Image-guided minimally invasive decompression (cervical, thoracic, and lumbar) is considered not medically necessary for Commercial products as the evidence is insufficient to determine the effects of the technology on health outcomes.

Evidence in the policy is insufficient to determine clinical benefit; procedure considered not medically necessary for Commercial members.

inv-02: BlueCHiP for Medicare — Coverage with Evidence Development (CED)

Covered when ALL of the following are met

Medicare CED Coverage: Percutaneous image-guided lumbar decompression (PILD) is covered by Medicare only when provided as part of a CMS‑approved clinical study meeting CMS Coverage with Evidence Development (CED) criteria and beneficiaries are enrolled in the approved study.

Claims for services provided in a CMS‑approved clinical study must be billed with the appropriate clinical research modifier (Q0 or Q1) per Medicare billing guidance.

The procedure is indicated only for central lumbar spinal stenosis. Percutaneous image-guided minimally invasive lumbar decompression (IG-MLD, aka MILD/PILD) is performed under fluoroscopic guidance to resect hypertrophied ligamentum flavum and small amounts of lamina to decompress the central canal. The devices and technique are not intended for use near the lateral neural elements and are contraindicated for disc procedures or treatment of nerve‑root compression/disc herniation. (Devices remain dorsal to the dura and are designed for perilaminar/interlaminar tissue resection.)

For Commercial products, image‑guided minimally invasive decompression (cervical, thoracic, and lumbar) is considered not medically necessary because the evidence is insufficient to determine the effect of the technology on health outcomes. Specific CPT/HCPCS codes associated with the procedure (for example, 0275T and G0276, and codes listed in the coding section such as 0274T) are identified in the policy as not medically necessary for Commercial members and may be subject to denial. Please refer to the coding section for code‑level guidance.

The policy distinguishes Commercial coverage from BlueCHiP for Medicare: Commercial plans do not cover IG‑MLD, while Medicare coverage may be available only under a CMS‑approved clinical study per the Medicare/CED provisions.

Coding and Billing Codes

Allowed for BlueCHiP for Medicare in CMS-approved clinical studyCPT | HCPCSCovered

G0276	Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial
0275T	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels; lumbar

Not medically necessary codes (Commercial and/or not allowed)CPTNot Covered

0274T

Percutaneous laminotomy/laminectomy (intralaminar approach) for decompression of neural elements ... cervical or thoracic

Codes explicitly listed as not medically necessary for Commercial productsCPT | HCPCSNot Covered

0275T	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements ... lumbar
G0276	Blinded procedure for lumbar stenosis, PILD or placebo-control, performed in an approved CED clinical trial

Required claim modifiers for clinical studiesModifier

Q0	Investigational clinical service provided in an approved clinical research study (Medicare modifier)
Q1	Routine clinical service provided in clinical research study that is in an approved clinical research study

Provider Actions and Billing Requirements

Prior Authorization

Prior Authorization / Benefits

Not applicable. Benefits may vary between contracts; please refer to the member's Evidence of Coverage (EOC) or Subscriber Agreement to determine prior authorization requirements or benefit coverage for this service.

Prior authorization: Check member EOC / Subscriber Agreement
If benefits do not cover procedure, submit for medical review per contract terms

Billing Rule

Billing Modifier Requirement for Medicare Clinical Studies

Claims for services rendered as part of a CMS‑approved clinical study must be billed with the appropriate clinical trial billing modifier. Medicare requires specific modifiers to designate routine clinical services versus investigational clinical services provided in an approved study.

Modifier Q1: Routine clinical service provided in a clinical research study that is in an approved clinical research study
Modifier Q0: Investigational clinical service provided in a clinical research study that is in an approved research study (Medicare claims filed without the Q0 modifier will deny as not medically necessary)

Documentation Required

Medicare Clinical Trial Documentation / Billing

When treating BlueCHiP for Medicare members as part of a CMS‑approved study, follow CMS and payer procedures for clinical trial billing and documentation. Documentation must demonstrate the member's participation in the approved clinical study and identify which services are part of the study versus routine care.

Follow the procedures for correct billing and documentation as outlined in the BlueCHiP for Medicare clinical trials policy.
Include study identifiers and documentation that the study is CMS‑approved/CED on the claim and in the medical record.
Use allowed codes (e.g., GO276, 0275T) only when rendered as part of an approved CMS study and documented accordingly.

Denial Risk

Commercial Denial Risk

For Commercial products, image‑guided minimally invasive decompression (IG‑MLD) is considered not medically necessary. Claims for IG‑MLD in Commercial members are subject to denial per contract terms.

IG‑MLD is not medically necessary for Commercial products — expect potential denial.
Review member contract and submit justification if seeking prior authorization or appeal following denial.

Background

Lumbar spinal stenosis (LSS) is narrowing of the spinal canal that produces neurogenic claudication—leg pain, numbness, or weakness that typically worsens with standing or walking and improves with sitting or forward flexion. Conventional posterior decompressive surgeries (eg, laminectomy, laminotomy) have established benefits but can be associated with postoperative morbidity and potential spinal instability. Percutaneous image‑guided minimally invasive lumbar decompression (IG‑MLD) is an ultra‑minimally invasive, fluoroscopically guided procedure developed to treat central LSS by resecting hypertrophied ligamentum flavum and small portions of lamina through a percutaneous cannula to decompress the central canal. Early studies report symptom and function improvements for selected patients, but available evidence is limited and at risk of bias, which has informed the policy's cautious coverage stance for commercial members and conditional coverage pathways for Medicare.

Definitions

IG-MLD / MILD / PILD — definition and alternative names

Formal namePercutaneous image-guided minimally invasive lumbar decompression (IG-MLD)

Common alternate namesMILD; PILD

Procedure descriptionFluoroscopically guided percutaneous procedure using a specialized cannula and tools to resect hypertrophied ligamentum flavum and small amounts of lamina to decompress the central spinal canal.

Intended indicationTreatment of central lumbar spinal stenosis with ligamentum flavum hypertrophy (neurogenic claudication).

Limitations / contraindicationsIntended only for central stenosis; not intended for disc procedures or use near lateral neural elements (cannot address nerve root compression or disc herniation).